⚡ Quick Verdict: Semax vs Selank
Both Semax and Selank are Russian-developed synthetic neuropeptides with overlapping but distinct research profiles. Semax is the more stimulating compound — primarily studied for cognitive enhancement, neuroprotection, and BDNF upregulation; best researched for acute mental performance, focus, and stress resilience without sedation. Selank is the more calming compound — studied for anxiolytic effects, stress modulation, and immune regulation through enkephalin-stabilising mechanisms; best researched for anxiety biology, stress response, and immuno-nootropic effects. For functional medicine researchers, the choice depends entirely on the research question: cognitive enhancement studies → Semax; anxiety and stress response studies → Selank; combined neurological research → both.
| Feature | Semax | Selank |
|---|---|---|
| Base Sequence | ACTH(4-7)–Pro-Gly-Pro synthetic analogue | Tuftsin (Thr-Lys-Pro-Arg) + Gly-Gly-Pro extension |
| Primary Effect | Cognitive enhancement, neuroprotection, BDNF upregulation | Anxiolytic, stress modulation, immune regulation |
| Research Origin | Russian Institute of Molecular Genetics | Institute of Molecular Genetics, Moscow |
| Administration | Intranasal (primary); subcutaneous in research | Intranasal (primary); subcutaneous in research |
| BDNF Effect | Strong upregulation documented | Modest/indirect BDNF modulation |
| Anxiolytic Effect | Mild stress resilience; not primarily anxiolytic | Primary pharmacological effect — well-documented |
| Human Evidence | Russian clinical trials (stroke, ADHD-type, cognition); approved in Russia | Russian clinical trials (anxiety, PTSD, immune); approved in Russia |
| Sedation Risk | Low — typically activating | Minimal — calming without sedation (unlike benzodiazepines) |
Table of Contents
- Overview: What Is Semax?
- Overview: What Is Selank?
- Mechanism Comparison: How Each Peptide Works
- Benefits Comparison: Cognitive, Anxiolytic, and Neuroprotective Research
- BDNF, Neuroplasticity, and Brain Health Research
- Anxiety and Stress Response Research
- Immune and Neuroinflammation Research
- Research Evidence Comparison
- Which Fits Different Research Profiles
- Key Research Numbers
- Frequently Asked Questions
- Related Articles
- Related Products
- Related Research Plans
- Scientific References
- Conclusion
Overview: What Is Semax?
Semax is a synthetic heptapeptide (7 amino acids) developed at the Institute of Molecular Genetics in Moscow during the 1980s and 1990s, originally as a neuroprotective agent for stroke and traumatic brain injury. Its sequence — Met-Glu-His-Phe-Pro-Gly-Pro — is based on the 4–7 position fragment of adrenocorticotropic hormone (ACTH), a pituitary peptide involved in stress response and cortisol regulation. However, Semax has been specifically engineered to lack the adrenocortical activity of ACTH — meaning it does not stimulate cortisol production — while retaining and amplifying the neuroprotective and cognitive-enhancing properties associated with this region of the ACTH molecule.
Semax is approved in Russia and Ukraine as a pharmaceutical agent for stroke treatment and prophylaxis of cognitive impairment, making it one of the few research peptides with actual national regulatory approval and a published human clinical trial base. It is available in Russia as a nasal spray (0.1% solution) and has been studied in doses ranging from intranasal micrograms to subcutaneous milligrams in animal and human research contexts.
The compound’s primary pharmacological signature is cognitive-enhancing and neuroprotective: research consistently documents improved memory, attention, processing speed, and stress resilience in animal models and in human populations studied in Russian clinical trials. Its BDNF-upregulating effect — one of the most consistent and well-characterised findings across multiple laboratories — provides a strong mechanistic basis for its cognitive research applications.
Overview: What Is Selank?
Selank is a synthetic heptapeptide developed at the same institute as Semax — the Institute of Molecular Genetics in Moscow — during the 1990s and early 2000s, with a fundamentally different design objective: anxiolysis without sedation, benzodiazepine-free stress modulation. Its sequence — Thr-Lys-Pro-Arg-Gly-Pro-Pro — is based on Tuftsin (Thr-Lys-Pro-Arg), an endogenous immunomodulatory tetrapeptide derived from IgG, with a C-terminal Gly-Pro-Pro extension added to enhance stability and central nervous system penetration.
Like Semax, Selank is approved in Russia as a pharmaceutical agent — specifically as an anxiolytic and nootropic — and has been the subject of Russian clinical trials in anxiety disorders, phobia, generalised anxiety disorder, and post-traumatic stress. Its Russian brand name is Selank, and it is available as a 0.15% nasal spray in that market.
Selank’s pharmacological profile is characterised by anxiolytic, anti-stress, and immunomodulatory effects without the sedation, tolerance development, or physical dependence associated with GABAergic anxiolytics (benzodiazepines). This profile is of particular research interest for functional medicine practitioners exploring non-GABAergic anxiety biology and the relationship between immune function and mental health.
Mechanism Comparison: How Each Peptide Works
Despite sharing a development origin and intranasal delivery route, Semax and Selank work through substantially different molecular mechanisms, which explains their distinct pharmacological profiles and research applications.
Semax’s primary mechanism involves upregulation of BDNF (Brain-Derived Neurotrophic Factor) — the key growth factor responsible for neuronal survival, synaptic plasticity, and hippocampal neurogenesis. Multiple studies document Semax-induced increases in BDNF mRNA and protein in cortical and hippocampal neurons, with downstream activation of TrkB receptors (BDNF’s primary receptor) and the PI3K-Akt and MAPK/ERK signalling cascades. These pathways regulate gene expression programs associated with long-term potentiation, memory consolidation, and neuronal resilience to ischemic stress. Semax also modulates serotonin and dopamine systems in a non-receptor-binding fashion, influencing monoamine neurotransmission through indirect mechanisms.
Selank’s primary mechanism operates through the enkephalin-degrading enzyme system. Selank is a competitive inhibitor of enkephalinase — the enzyme responsible for degrading endogenous enkephalins (met-enkephalin and leu-enkephalin), which are natural opioid peptides involved in anxiety modulation, stress response regulation, and immune function. By preventing enkephalin breakdown, Selank effectively amplifies endogenous opioid signalling in a physiological, feedback-controlled manner — unlike exogenous opioids that bypass this regulation entirely. Additionally, Selank’s Tuftsin-derived sequence confers immunomodulatory properties through interaction with macrophage and T-cell Tuftsin receptors, providing an immune research dimension absent from Semax.
Key Insight: A crucial mechanistic distinction between Selank and other anxiolytics is that Selank amplifies the body’s own enkephalin signalling rather than introducing an exogenous receptor agonist. This means that Selank’s anxiolytic effects are inherently self-limiting (bounded by endogenous enkephalin availability) and unlikely to produce tolerance or dependence — a critical safety advantage in the research context and a major differentiator from benzodiazepine research models.
Why It Matters: For functional medicine practitioners researching non-GABAergic anxiety treatment approaches, this enkephalin-amplification mechanism provides a model for anxiety modulation that is biologically and pharmacologically distinct from all currently approved anxiolytics — opening research questions about whether enkephalin system modulation can provide therapeutic benefit without the risks of GABAergic or opioid receptor approaches.
Benefits Comparison: Cognitive, Anxiolytic, and Neuroprotective Research
Semax demonstrates the strongest research profile for cognitive enhancement and neuroprotection. Animal studies document improvements in spatial memory (Morris water maze), attention and learning (avoidance conditioning), and cognitive resilience under ischemic conditions. Human studies in stroke patients show improved cognitive recovery metrics, and smaller studies in healthy volunteers report enhanced attention, working memory, and stress resilience during cognitively demanding tasks.
Selank demonstrates the strongest research profile for anxiety, stress response, and mood regulation. Animal studies consistently show anxiolytic effects in elevated plus maze, open field, and forced swim test models — standard preclinical anxiety assays. Human clinical trials in patients with anxiety disorders show reductions in Hamilton Anxiety Rating Scale (HAMA) scores comparable to benzodiazepines but without sedation or withdrawal effects. Studies in healthy volunteers under laboratory stress conditions show Selank-treated subjects maintain better performance on attention and short-term memory tasks under stress — a cognitive-preserving effect that differs from Semax’s direct cognitive enhancement mechanism.
Both peptides share neuroprotective properties in ischemia models, though through different pathways — Semax through BDNF-mediated neuronal survival; Selank through anti-inflammatory and enkephalin-mediated cytoprotective effects. For functional medicine researchers interested in comprehensive neuroregenerative protocols, this mechanistic complementarity makes them interesting candidates for combined research designs.
BDNF, Neuroplasticity, and Brain Health Research
Brain-Derived Neurotrophic Factor (BDNF) is arguably the most important growth factor for brain health, cognitive function, and neuroplasticity in adult humans. It supports the survival of existing neurons, promotes the growth and differentiation of new neurons and synapses, and plays a central role in long-term potentiation (LTP) — the cellular mechanism of learning and memory. BDNF levels decline with age, depression, chronic stress, and sedentary behaviour — a pattern correlated with cognitive decline, increased Alzheimer’s risk, and mood disorders.
Semax’s consistent BDNF-upregulating effect across multiple independent studies positions it as a research tool of significant interest in the neuroplasticity and cognitive ageing research space. Studies in rodent models have documented 2–4 fold increases in hippocampal BDNF expression following Semax administration, with effects observed in both acute single-dose and chronic treatment paradigms. The TrkB receptor pathway downstream of BDNF activation promotes synaptogenesis, neurogenesis in the hippocampal dentate gyrus, and AMPA receptor membrane insertion — mechanistic correlates of improved memory encoding.
For functional medicine practitioners, BDNF is increasingly recognised as a key biomarker of brain health and cognitive reserve. Exercise is the most established BDNF upregulator (interestingly, overlapping with MOTS-C’s exercise-mimetic research profile), but compounds like Semax that pharmacologically upregulate BDNF are of research interest as potential tools for studying BDNF’s role in cognitive resilience — particularly in populations where exercise capacity is limited.
Anxiety and Stress Response Research
Selank’s anxiolytic research profile is one of the more extensively documented among nootropic peptides, particularly given its Russian clinical trial base in actual anxiety disorder patients rather than solely healthy volunteer studies. Clinical trials using standardised anxiety rating scales — including the Hamilton Anxiety Rating Scale (HAMA) and Spielberger State-Trait Anxiety Inventory (STAI) — have documented statistically significant anxiety reduction with Selank treatment in generalised anxiety disorder populations.
The mechanistic basis — enkephalin system amplification — is increasingly connected to the broader field of stress biology research. Enkephalins are part of the endogenous stress response system, modulating the HPA (hypothalamic-pituitary-adrenal) axis activation in response to psychosocial stress. Selank’s ability to amplify this endogenous buffering system provides a research model for studying how the enkephalin system can be pharmacologically supported without the adverse effects of exogenous opioids or GABAergic sedatives.
Additionally, chronic stress impairs BDNF expression — creating an interesting research connection between Selank and Semax: Selank’s stress-reduction effects may indirectly protect BDNF levels (by reducing stress-induced BDNF suppression), while Semax directly upregulates BDNF synthesis. Some research protocols explore this complementarity explicitly.
Key Insight: In both preclinical and clinical Selank studies, the anxiolytic effect is consistently observed without measurable sedation, motor impairment, or disruption of cognitive performance — unlike benzodiazepines, which produce anxiolysis but impair memory consolidation (anterograde amnesia) and motor coordination. Selank’s studies in anxious populations under cognitive task conditions show anxiety reduction accompanied by preserved or improved task performance.
Why It Matters: For functional medicine practitioners researching anxiety interventions for high-performing professionals, executives, and digital nomads — populations that prioritise maintaining cognitive performance alongside anxiety management — Selank’s profile of anxiolysis-without-sedation represents a pharmacologically distinctive research model that warrants comparison with current anxiolytic pharmacology in rigorous clinical trial settings.
Immune and Neuroinflammation Research
Selank’s Tuftsin-based structure gives it immunomodulatory properties not shared by Semax. Tuftsin is a naturally occurring immunoregulatory peptide that activates macrophages, natural killer cells, and T-lymphocytes through specific Tuftsin receptors on immune cell surfaces. Selank’s Tuftsin-derived sequence retains this immunostimulatory activity, making it a unique neuropeptide with simultaneous CNS and immune research applications.
Research documents Selank’s ability to modulate cytokine profiles — specifically reducing pro-inflammatory cytokines including IL-6, TNF-α, and IL-1β while increasing regulatory cytokines including IL-10. This cytokine-modulating profile is of particular interest in the context of neuroinflammation — the increasingly recognised role of chronic low-grade brain inflammation in depression, anxiety disorders, cognitive decline, and neurodegenerative disease. The bidirectional immune-brain axis research field (psychoneuroimmunology) represents a natural research home for a compound with simultaneous anxiolytic and immunomodulatory properties.
Semax also has documented anti-inflammatory effects in the brain — primarily through its neuroprotective activity in ischemia models, where it reduces neuroinflammatory cascades following blood-brain barrier disruption. However, Semax’s immune effects are primarily CNS-localised rather than systemic, whereas Selank’s Tuftsin-derived mechanism operates on both central and peripheral immune cells.
Research Evidence Comparison
| Research Area | Semax Evidence | Selank Evidence |
|---|---|---|
| BDNF Upregulation | Strong — multiple animal studies; 2–4x hippocampal BDNF increase | Modest indirect effect via stress reduction |
| Cognitive Enhancement | Well-documented in animals and human clinical trials | Cognitive preservation under stress (not direct enhancement) |
| Anxiolytic Effects | Mild stress resilience; not primary pharmacological effect | Primary effect — HAMA scale reductions in human clinical trials |
| Neuroprotection (Ischemia) | Strong — approved for stroke in Russia; multiple human trials | Documented in animal ischemia models; less clinical data |
| Immune Modulation | CNS anti-inflammatory; systemic immune effects limited | Systemic and CNS immune modulation via Tuftsin mechanism |
| Human Clinical Data | Russian clinical trials — stroke, cognitive impairment; approved in Russia | Russian clinical trials — anxiety disorders, phobia; approved in Russia |
| Independent Replication | Some (BDNF upregulation confirmed in international literature) | Limited outside Russian institutions |
Which Fits Different Research Profiles
For functional medicine practitioners designing research protocols, the choice between Semax and Selank should be driven by the specific research question and patient/subject profile. Semax is the more appropriate research compound for studies investigating cognitive enhancement, neuroprotection from ischemic or traumatic brain injury, BDNF-mediated neuroplasticity, or attention and working memory optimisation in healthy subjects. Its activating profile makes it appropriate for daytime research use and its BDNF mechanism connects it to the broader neuroplasticity research field.
Selank is more appropriate for research into anxiety biology, HPA axis stress modulation, non-sedating anxiolysis mechanisms, immune-neurological interactions, and the psychoneuroimmunology of stress and mood disorders. Its anti-inflammatory cytokine profile makes it relevant to neuroinflammation research, and its lack of sedation or cognitive impairment makes it research-appropriate for subjects who need to maintain cognitive performance during treatment.
A third research design option — combined Semax and Selank protocols — is explored in some Russian research, based on the rationale that their complementary mechanisms (direct BDNF upregulation + stress/anxiety reduction) may produce additive neuro-optimisation effects. This combination research remains in early stages and requires dedicated controlled studies to evaluate.
Key Research Numbers
Statistics Section: Semax and Selank in Numbers
- 7 amino acids — Length of both Semax and Selank peptides
- 2–4x — Increase in hippocampal BDNF expression documented with Semax in rodent studies
- ACTH(4-7) — The ACTH fragment that forms the structural basis of Semax
- Tuftsin — The endogenous immunomodulatory tetrapeptide forming the basis of Selank
- HAMA scale — Hamilton Anxiety Rating Scale used as primary endpoint in Selank clinical trials
- 1980s–1990s — Development decade for both Semax and Selank at the Institute of Molecular Genetics, Moscow
- Russia and Ukraine — Jurisdictions where Semax holds regulatory pharmaceutical approval
- Russia — Jurisdiction where Selank holds regulatory pharmaceutical approval as an anxiolytic/nootropic
- 0.1% — Semax intranasal solution concentration in the Russian pharmaceutical product
Frequently Asked Questions
A: Semax primarily enhances cognition, neuroprotection, and BDNF upregulation through ACTH-derived mechanisms — it is an activating compound used in cognitive enhancement and stroke research. Selank is primarily an anxiolytic and immunomodulator that works through enkephalin system amplification (Tuftsin-derived mechanism) — it reduces anxiety and stress without sedation. They share a Russian research origin and intranasal delivery route but have distinct mechanisms and applications.
A: Both are approved pharmaceutical agents in Russia — Semax for stroke treatment and cognitive impairment prophylaxis, Selank as an anxiolytic and nootropic. They are NOT approved in the US, EU, Australia, or most Western jurisdictions, where they are classified as research chemicals or unapproved drugs. Functional medicine practitioners outside Russia should be aware of this regulatory status when discussing these compounds.
A: Research shows Semax increases BDNF mRNA transcription in cortical and hippocampal neurons, with downstream effects on TrkB receptor activation and MAPK/ERK signalling — pathways regulating neuronal survival, synaptic plasticity, and memory consolidation. The mechanism connecting Semax’s ACTH-derived structure to BDNF transcription is not fully characterised but is consistently documented across multiple independent research groups.
A: This is one of Selank’s most distinctive research features. Both preclinical (animal model) and clinical (human) studies consistently show that Selank’s anxiolytic effects are achieved without measurable sedation, motor impairment, or cognitive impairment — in contrast to benzodiazepines, which produce sedation and anterograde amnesia alongside anxiolysis. Some studies report that Selank-treated subjects maintain or improve cognitive task performance while experiencing anxiety reduction.
A: Selank’s base sequence is derived from Tuftsin — an endogenous tetrapeptide (Thr-Lys-Pro-Arg) from IgG that acts as a natural immunomodulator, activating macrophages, NK cells, and T-lymphocytes through Tuftsin receptors. This gives Selank simultaneous CNS (anxiolytic) and peripheral immune (immunomodulatory) properties. Research documents Selank’s effects on cytokine profiles — reducing pro-inflammatory IL-6, TNF-α, IL-1β and increasing regulatory IL-10 — making it relevant to psychoneuroimmunology research.
A: The answer depends entirely on the research question. For investigations into cognitive enhancement, neuroprotection, BDNF biology, and neuroplasticity → Semax. For investigations into anxiety disorders, stress response, HPA axis modulation, non-GABAergic anxiolysis, and immune-neurological interactions → Selank. For comprehensive neuroregulation studies combining cognitive and emotional domains → consider both in sequential or combined research designs, noting they have complementary rather than overlapping mechanisms.
A: Both peptides are primarily studied via intranasal administration — a route that facilitates direct olfactory-nerve pathway delivery to the CNS, bypassing the blood-brain barrier and reducing peripheral degradation. Research has also used subcutaneous injection in animal and some human studies. Intranasal delivery requires appropriate preparation (sterile nasal spray formulations) and is subject to variability in absorption based on nasal anatomy and mucosal condition.
A: Vietnam Peptides supplies research-grade Semax 10mg and Selank 10mg for investigators studying neuropeptide pharmacology, BDNF biology, anxiety mechanisms, and neuroimmunology. Products are supplied strictly for scientific research. Researchers should review local regulatory requirements before procurement.
Related Articles
- Vietnam Peptides Knowledge Hub — neuropeptide research guides and peptide science education
- Peptide FAQ: Research, Storage and Usage
- Browse Research Peptides — Nootropics and Cognitive Research
Related Research Products
Research-grade ACTH-derived nootropic neuropeptide for BDNF upregulation, cognitive enhancement, and neuroprotection research.
View Product →Research-grade Tuftsin-derived anxiolytic neuropeptide for anxiety biology, stress response, and neuroimmunological research.
View Product →Related Research Plans
For functional medicine practitioners investigating cognitive health, neuroprotection, anxiety biology, and neuroinflammation, the Vietnam Peptides Longevity Plan provides compound selection frameworks that encompass neuropeptide and brain health research dimensions.
Explore the Longevity Plan →Scientific References
- Davydova TV, Fomina VG, Kost NV, et al. (2007). Semax administration affects the opioid system of rats. Bull Exp Biol Med. 144(1):87–9. DOI: 10.1007/s10517-007-0258-z
- Manchenko DM, Volodina MA, Glazova NY, et al. (2012). Semax, an analog of ACTH(4-10), affects the behaviour of WKY and SHR rats and modulates brain BDNF expression. Bull Exp Biol Med. 154(2):214–7. DOI: 10.1007/s10517-012-1921-x
- Zozulya AA, Neznamov GG, Sanayeva PA, et al. (2001). Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the treatment of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 101(12):4–17. PMID: 11842881
- Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskii II. (2010). Comparison of the effects of Selank and short peptides of the tuftsin group on the behaviour of animals in stress. Eksp Klin Farmakol. 73(8):6–8. PMID: 20936915
- Kolik LG, Nadorova AV, Kozlovskaya MM. (2014). Efficacy of peptide anxiolytic selank and novel tripeptide analogues in an animal model of alcohol withdrawal anxiety. Bull Exp Biol Med. 157(1):52–5. DOI: 10.1007/s10517-014-2494-5
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Semax, an analogue of ACTH(4-7), regulates expressions of BDNF and its receptor in the rat hippocampus. J Mol Neurosci. 28(2):179–87. DOI: 10.1385/JMN:28:2:179
- Konstantinopolsky MA, Serkov IV, Poletaeva II. (2004). Effects of peptide ACTH analogue semax on the behavior of rats under emotional stress. Zh Vyssh Nerv Deiat Im I P Pavlova. 54(3):349–54. PMID: 15354793
- Uchakina ON, Uchakin PN, Mabry RL, et al. (2008). Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 108(5):71–5. PMID: 18577940
Conclusion
Semax and Selank represent two distinct and complementary research compounds within the Russian neuropeptide research tradition. Semax offers a well-characterised cognitive enhancement and neuroprotection profile driven by BDNF upregulation and ACTH-derived mechanisms, with Russian regulatory approval and clinical data in stroke and cognitive impairment. Selank provides a unique anxiolytic-without-sedation pharmacological model through enkephalin system amplification and Tuftsin-derived immunomodulation, with Russian regulatory approval and clinical data in anxiety disorders.
For functional medicine practitioners navigating the growing landscape of nootropic and neuropeptide research, these compounds offer research models that differ fundamentally from existing pharmacological paradigms — BDNF biology (Semax) and non-GABAergic anxiolysis (Selank) — that are relevant to some of the most pressing unmet research needs in neurology, psychiatry, and integrative medicine.
Vietnam Peptides supplies research-grade Semax 10mg and Selank 10mg for qualified investigators. Explore both products at the Products Page and visit the Knowledge Hub for additional neuropeptide research resources.
Primary Entity: Semax vs Selank — Russian Neuropeptide Comparison
Related Entities: BDNF (Brain-Derived Neurotrophic Factor), TrkB Receptor, ACTH(4-7), Tuftsin, Enkephalins, Enkephalinase, HPA Axis, Generalized Anxiety Disorder, Hamilton Anxiety Rating Scale (HAMA), Cognitive Enhancement, Neuroprotection, Psychoneuroimmunology, Institute of Molecular Genetics Moscow, Neuroinflammation, IL-6, TNF-α
Search Intent: Comparison / Decision Making — Semax vs Selank for functional medicine research; which to use for cognitive vs anxiety investigations
Key Questions Answered: What is the difference between Semax and Selank? How does Semax increase BDNF? How does Selank work as anxiolytic? Are Semax and Selank approved? Which should I research first? Semax vs Selank for functional medicine?
Evidence Sources: Dolotov et al. 2006 (J Mol Neurosci), Manchenko et al. 2012 (Bull Exp Biol Med), Zozulya et al. 2001, Semenova et al. 2010, Uchakina et al. 2008, Kolik et al. 2014
Relevant User Profiles: Functional Medicine Practitioners, Neuroscience Researchers, Biohackers, Longevity Enthusiasts, Mental Health Researchers, Executives, Digital Nomads researching cognitive performance
Knowledge Graph Connections: Semax → BDNF → Neuroplasticity → Cognitive Enhancement → Neuroprotection → Selank → Enkephalin System → Anxiolytic → Stress Response → Immune Modulation → Functional Medicine → Research Peptides Vietnam